NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

Antipsychotic weight gain and inflammation in children and adolescents

By Mindo - 23rd Nov 2020

Tape measure on bathroom scales on a white tiled background with a bath robe and copy space.Click on the link to see more of my nutrition and medical images

College of Psychiatrists of Ireland, Online Winter Conference, 6 November 2020

Dr Karen Conlan is a Senior Registrar in Child and Adolescent Psychiatry. She is currently carrying out a PhD in Trinity Centre for Health Sciences, Dublin, and is investigating whether antipsychotic related weight gain in children and adolescents is associated with inflammation. This is an important question as inflammation is linked to both physical and mental disorders. Second generation antipsychotics are often associated with rapid weight gain and significant cardiometabolic dysregulation, with children appearing to be more at risk than adults. This weight gain can lead to obesity, and obesity is associated with chronic low-grade inflammation. This is significant as chronic inflammation is a major driver of insulin resistance and the development of Type 2 diabetes mellitus (T2DM).

Therefore, the hypothesis of Dr Conlan’s research is that second generation antipsychotics cause inflammation, which drives the associated cardiometabolic side effects of these medications. Ten children and adolescents were recruited for this study. Blood samples were taken before starting antipsychotic medication, and then three, six, and 12 months after treatment was initiated. These samples were used to measure systemic levels of inflammation and immune cell populations. Clinical parameters such as BMI percentile, lipid level, insulin level, and glucose level were also collected. Within three months of starting the medication, the BMI of participants increased significantly. Leptin, involved in glucose and lipid metabolism, was also increased, alongside the inflammatory marker IL-17. These measurements either increased further or remained consistently high across the 12-month period.

On further inspection, it was found that the inflammatory marker IL-17 was coming from three distinct immune cell populations: CD4 T-cells, Gamma Delta T-cells, and MAIT cells. Furthermore, MAIT cells increased in study participants after starting antipsychotic medication; this increase should only be observed in the presence of infection, but it has also been observed in obese children not taking antipsychotics. Dr Conlan told the CPsychI Winter Conference that these results are significant, as elevated levels of IL-17 have been linked to the development of T2DM, obesity related asthma, and fibrosis in the liver of patients with non-alcoholic fatty liver disease (NAFLD), while a recent mouse study demonstrated that an increase in MAIT cells promoted metabolic dysfunction.

Overall this study demonstrates that within three months of starting antipsychotic medication, children and adolescents develop an inflammatory phenotype. Although this inflammatory state did not translate into metabolic dysfunction within the timeframe of this study, other studies have demonstrated that inflammation in obese children precedes metabolic dysfunction. Furthermore, adult studies have demonstrated that antipsychotic medication impacts metabolic health, promoting hyperlipidaemia, insulin resistance, and T2DMs. Dr Conlan concluded that further research in this area has the potential to identify novel targets, which could prevent these side effects from antipsychotic medication.

Leave a Reply

Latest Issue
The Medical Independent 20th February
The Medical Independent 20th February 2024

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read